OS Therapies Inc OSTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.72
- Day Range
- $1.59–1.73
- 52-Week Range
- $1.15–2.57
- Bid/Ask
- $1.63 / $1.71
- Shares Outstanding
- 44.54M
- Market Cap
- $74.82M
- Volume/Avg
- 757,866 / 821,876
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 5
- Website
- https://www.ostherapies.com
Valuation
|
Metric
|
OSTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OSTX
|
|---|---|
Quick Ratio | 0.05 |
Current Ratio | 0.05 |
Interest Coverage | −467.17 |
Quick Ratio
OSTX
Profitability
|
Metric
|
OSTX
|
|---|---|
Return on Assets (Normalized) | −401.30% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
OSTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|cdFNYzq | LOCK|r$vLv | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|F#!!y#S | LOCK|>!n< | $70B | |||
| argenx SE ADR
ARGX
| LOCK|gJw#>> | LOCK|hS> | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Y@tB%^N | LOCK|KLRrz | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|MRZcDl^ | LOCK|QNX | $36B | |||
| Moderna Inc
MRNA
| LOCK|K%Z@#c | LOCK|$? | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|fFb!%%Zf | LOCK|DLPz | $25B | |||
| Incyte Corp
INCY
| LOCK|j!Wk!L | LOCK|p! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#sxVr@ | LOCK|@%J | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<!%@R^ | LOCK|^$ | $17B |
United States